By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

Archive for September, 2018

Lumos Pharma Acquires Candidate for Oral Treatment of Growth Hormone Deficiency

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.  Lumos plans to initiate a...Read More

10 CTD Study Sites Now Open

The Vigilan Study – Observational Study of Creatine Transporter Deficiency (CTD) of Males, now has ten study sites open for patient enrollment. Males with CTD will be screened at university clinics. Once enrolled in the study, participants will undergo a series of age-appropriate tests of physical and intellectual abilities. Follow-up testing will occur every 6...Read More